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We examined the population dynamics of human immunodeficiency virus type 1 pro variants during the
evolution of resistance to the protease inhibitor ritonavir (RTV) in vivo. pro variants were followed in subjects
who had added RTV to their previously failed reverse transcriptase inhibitor therapy using a heteroduplex
tracking assay designed to detect common resistance-associated mutations. In most cases the initial variant
appeared rapidly within 2 to 3 months followed by one or more subsequent population turnovers. Some of the
subsequent transitions between variants were rapid, and some were prolonged with the coexistence of multiple
variants. In several cases variants without resistance mutations persisted despite the emergence of new
variants with an increasing number of resistance-associated mutations. Based on the rate of turnover of pro
variants in the RTV-treated subjects we estimated that the mean fitness of newly emerging variants was
increased 1.2-fold (range, 1.02 to 1.8) relative to their predecessors. A subset of pro genes was introduced into
infectious molecular clones. The corresponding viruses displayed impaired replication capacity and reduced
susceptibility to RTV. A subset of these clones also showed increased susceptibility to two nonnucleoside
reverse transcriptase inhibitors and the protease inhibitor saquinavir. Finally, a significant correlation be-
tween the reduced replication capacity and reduced processing at the gag NC-p1 processing site was noted. Our
results reveal a complexity of patterns in the evolution of resistance to a protease inhibitor. In addition, these
results suggest that selection for resistance to one protease inhibitor can have pleiotropic effects that can affect
fitness and susceptibility to other drugs.
Protease inhibitors (PIs) potently inhibit human immunode-
ficiency virus type 1 (HIV-1) replication, and their initial in-
troduction into combination antiretroviral therapy was associ-
ated with a significant decrease of HIV-1-associated mortality
and morbidity (41, 45). However, in clinical practice, virologic
failure of protease inhibitor-containing therapy occurs in a
significant fraction of the treated population (19, 22, 42, 46, 52,
70). Virologic failure of protease inhibitor treatment is often
due to the selection of HIV-1 strains with mutations in the pro
gene, which encodes the viral protease (PR), and in specific
protease cleavage sites encoded in the gag gene that collec-
tively confer reduced drug susceptibility to the harboring strain
(11, 12, 28, 36, 43, 47, 72).
The resistance mutations are hypothesized to be largely pre-
existing, generated by the highly error-prone and rapid repli-
cation of HIV-1 in large virus populations (5, 10, 57). However,
in PI-naı̈ve subjects, some critical resistance mutations cannot
be detected or can only be detected at very low levels, suggest-
ing that these mutations may confer a selective disadvantage
relative to wild-type HIV-1 strains (3, 18, 25, 32, 34, 63). In-
deed, it has been shown that the catalytic efficiency of protease
is reduced by PI resistance-associated mutations, that polypro-
tein processing in strains bearing resistance mutations is in-
complete, and that replication capacity, fitness, and infectivity
are reduced compared to those in drug-susceptible strains (4,
9, 13, 18, 27, 29, 36, 39, 40, 44, 51, 58, 62, 64, 71). Some
mutations in pro and protease cleavage sites in gag have been
found to partially compensate for the loss of fitness and enzy-
matic activity (12, 36, 40, 62, 72).
In vivo, PI resistance mutations accumulate in an ordered
fashion (18, 43, 72). However, the population genetics that
underlies this macroscopically observed accumulation of mu-
tations in pro remains poorly understood. In the present study,
we characterized the population genetics of pro variants during
the evolution of ritonavir (RTV) resistance in subjects who
participated in an RTV efficacy trial (7) by using a multiple
site-specific heteroduplex tracking assay (MSS-HTA) capable
of detecting point mutations at positions 46, 48, 54, 82, 84, and
90 (55). This method allows pro genotypes with different num-
bers of mutations, mostly resistance related, to be quantitated.
Moreover we analyzed the drug susceptibility and replication
capacity of molecular clones with pro sequences derived from
treated subjects at different times. These studies reveal com-
plexity in the patterns of evolution of RTV resistance and
demonstrate pleiotropic effects of these resistance mutations
on viral fitness and susceptibility to other inhibitors. Finally, we
correlated the loss in fitness with underprocessing of the
NC-p1 protease cleavage site.
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MATERIALS AND METHODS
Blood plasma samples. Blood plasma samples were obtained with institutional
review board approval unlinked to subject identifiers and as excess tissue sam-
ples. The blood plasma samples are from subjects who participated in the virol-
ogy substudy of the ritonavir efficacy trial reported by Cameron et al. (7) and
were provided by Dale Kempf (Abbott Laboratories). In this trial, ritonavir
therapy was initiated in protease inhibitor-naı̈ve subjects while maintaining their
ongoing failed nucleoside reverse transcriptase inhibitor regimen. Under these
circumstances the added RTV approximated monotherapy and most subjects
experienced only a transient reduction in virus load followed by rebound. All
subjects had CD4 T-cell counts below 100/l at entry.
RNA isolation, RT-PCR, and heteroduplex tracking assay. Procedures for
RNA isolation, reverse transcriptase PCR (RT-PCR), and the HTA were carried
out as described previously (55). Briefly, viral RNA was isolated from 140 l of
blood plasma or from a pellet containing virus particles obtained by centrifuga-
tion of 1 ml of blood plasma (25,000  g, 1.5 h). The RNA was purified using the
QIAmp Viral RNA kit (QIAGEN) according to the manufacturer’s instructions.
All nucleotide numbering is based on the HIV-1 Hxb molecularly cloned ge-
nome. Primers PRAMPUP (5-[Hxb2305]-AACTAAAGGAAGCTCTATTAG
ATACAGGAG-[Hxb2334]-3) and PRAMPDW (5-[Hxb2551]-GGAAAATTT
AAAGTGCAACCAATCTGA-[Hxb2525]-3) were used for reverse transcription
(avian myeloblastosis virus reverse transcriptase, 42°C, 45 min) and PCR (1 cycle
of 95°C for 3 min, 56°C for 60 s, and 68°C for 60 s; 40 cycles of 95°C for 40 s, 56°C
for 60 s, and 68°C for 60 s to 4 min) to obtain an amplified product spanning
codons 18 to 99 of the pro gene. For the heteroduplex tracking assay, 5-l
aliquots of the unpurified PCR-amplified DNA fragments were mixed with 0.1
g 33P-labeled, multiple site-specific probe 6.1 (for sequence, see reference 55)
in annealing buffer (100 mM NaCl, 10 mM Tris-HCl, pH 7.5, and 2 mM EDTA)
in a total volume of 10 l. This mixture was heat denatured, and DNA strands
were allowed to anneal at room temperature to form probe-target heterodu-
plexes. The heteroduplexes were subjected to native polyacrylamide gel electro-
phoresis (PAGE) (12%; acrylamide-bisacrylamide ratio  61.5:1) in 1 Tris-
borate-EDTA gel buffer (60). After separation, the heteroduplexes were
visualized by autoradiography. Quantitative analysis was performed by storage
phosphor autoradiography with a Storm 840 PhosphorImager using the Image-
Quant software (Molecular Dynamics).
Estimation of relative fitness of variants during ritonavir treatment. Relative
fitness of two variants or one variant compared to all other variants present
concurrently was estimated as described previously (20). In brief, the logarithm
of the ratio of the abundance of two variants (ln[variant 1/variant 2]) is plotted
against time in generations. The slope of this line is an estimate of the selective
advantage of variant 1 (s). The fold change of the ratio per generation (eslope) is
referred to as relative fitness.
Sequence determination. The sequence of virus variants corresponding to
HTA bands was determined by sequencing a PCR product directly if, by HTA,
there was only a single variant present in the amplified product. If multiple
variants were present, the amplified DNA fragment was cloned into the PCR
cloning vector pT7blue (Novagen), individual clones were screened by HTA and
assigned to groups corresponding to HTA bands, and several clones from
each group were sequenced. RT-PCR products for sequence determination
were either the same as the RT-PCR products used for HTA analysis or were
generated using primers USPR (5-[Hxb2147]-CAGAGCCAACAGCCCCAC-
[Hxb2164]-3) and DSPR (5-[Hxb2605]-GGGCCATCCATTCCTGGC-[Hxb2588]
-3), which amplify a fragment from the p6 coding region in gag to the 5 end of
the RT coding domain in pol.
Construction of recombinant viral genomes. DNA fragments spanning nucle-
otides 2147 to 2605 (Hxb numbering, from the 3 end of the p6 coding domain
to the 5 end of the RT coding domain) were generated using primers USPR and
DSPR from viral RNA prepared from three subjects (three time points each) as
described above. In a second round of amplification, this DNA fragment was
mixed with a DNA fragment derived from the HIV-1 Hxb cloned genome (54)
spanning nucleotides 1994 to 2174, the primers PRBSP (5-[Hxb1994]-CCAGA
AATTGCAGGGCCCC-[Hxb2012]-3; underlined nucleotides indicate a
Bsp120I site), and PRRSR (5-[Hxb2607]-TCGGACCGTCCAATTCCTGGC-
[Hxb2588]-3; underlined nucleotides indicate a RsrII site) at 2 M each, in a
solution containing 0.2 mM each deoxynucleoside triphosphate (dNTP), 10 mM
KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.8), 2 mM MgSO4, 0.1% Triton
X-100, and 2 U of Vent DNA polymerase (New England BioLabs). PCR was
performed in a Stratagene 40 Robocycler (1 cycle of 95°C for 3 min, 54°C for 60 s,
and 72°C for 90 s; 25 cycles of 95°C for 45 s, 54°C for 60 s, and 72°C for 90 s; 1
cycle of 95°C for 45 s, 54°C for 60 s, and 72°C for 4 min), and the resulting
612-nucleotide fragment, flanked by Bsp120I and RsrII sites, was cloned blunt
into pT7blue. Clones were screened by HTA as described above, and the se-
quence of several clones representing each HTA band was determined. The
Bsp120I/RsrII fragment of a clone with a sequence close to the consensus
sequence of the corresponding HTA band was ligated into the Bsp120I and RsrII
sites of the pCadNBspBcl plasmid (S. Pettit and R. Swanstrom, unpublished).
This molecular clone contains the XbaI (Hxb1089; p17 coding domain)-to-
EcoRV (Hxb2980; RT coding domain) fragment of Hxb within the NL4-3 back-
bone (1). The Bsp120I (Hxb2007)-to-BclI (Hxb2430) fragment has been deleted
from this clone. From the three subjects, a total of 10 infectious clones were
constructed.
Drug susceptibility determination and single-cycle replication capacity assay.
Single-cycle replication capacity and drug susceptibility were measured using a
replication-incompetent HIV-1 vector in which a luciferase gene has been in-
serted into a deleted portion of the env gene as described previously (8, 50). The
patient-derived sequences in these vectors span nucleotides 2147 to 2605 (Hxb
numbering) as described in the previous section.
Virus stocks. For transfection, 293 cells were seeded at 4  105 cells/well in
six-well plates. One day after seeding, the cultures were transfected with 0.8 g
of plasmid DNA using Effectene reagents (QIAGEN) according to the manu-
facturer’s instructions. Virus-containing supernatants were collected 48 h after
transfection, clarified by centrifugation for 1 min at 3,000  g, and stored in
aliquots at 80°C.
RT activity assay. The activity of reverse transcriptase in culture supernatants
was measured as described previously (6) with the following modifications. The
radionucleotide incorporated into the nascent DNA strand was 33P, a vacuum
manifold (Bio-Rad) was used to capture the newly synthesized DNA on anion-
exchange paper, and storage phosphor autoradiography (Storm 840 Phospho-
rImager; Molecular Devices) was used to quantitate incorporated radioactivity.
Quantitative determination of capsid protein p24. The amount of the p24
capsid protein (CA) in transfection supernatants was measured with an enzyme-
linked immunosorbent assay using a commercially available set of reagents (New
England Nuclear) according to the manufacturer’s instructions.
Specific infectivity assay. Virus stocks were generated by transfection of plas-
mid DNA into 293 cells in triplicate. For each transfection, RT activity and the
amount of CA were measured as described above. Virus titers in transfection
supernatants were determined with the multinuclear activation of a galactosidase
indicator (MAGI) assay (31). Specific infectivity was calculated as the number of
infectious units per ng of CA or per unit of RT activity and normalized to the
parental strain.
Analysis of Gag processing. A 500-l aliquot of transfection supernatant
containing HIV-1 virions was centrifuged at 25,000  g for 1.5 h in a microcen-
trifuge. Pellets containing virus particles were resuspended and lysed in 50 l
sodium dodecyl sulfate (SDS) sample buffer (45 mM Tris-HCl, pH 8.45, 12%
[vol/vol] glycerol, 4% [wt/vol] sodium dodecyl sulfate, 50 mM dithiothreitol,
0.0075% Coomassie blue G, 0.0025% phenol red). A 5-l aliquot of the lysed
virus particles was subjected to denaturing SDS-PAGE as described previously
(61). Proteins were transferred to polyvinylidene difluoride membrane (Hy-
bondP; Amersham) and viral proteins were detected immunologically with either
a polyclonal rabbit anti-p15 antibody (provided by S. Erickson-Viitanen) or an
anti-HIV-1 human antiserum, using enhanced chemiluminescence (ECLplus;
Amersham). ECLplus reagents allow the detection of luminescence as well as
blue-excited fluorescence (Storm 840 PhosphorImager; Molecular Devices) for
quantitation.
Statistical analysis. Statistical analysis was carried out with the R language
(http://www.r-project.org). Associations between different parameters were esti-
mated with Spearman’s correlation coefficient  or linear regression. The signif-
icance of differences in mean values was estimated with Student’s t test.
Nucleotide sequence accession number. All sequences have been submitted to
GenBank and have been assigned the consecutive accession numbers AY678610
to AY679067.
RESULTS
Dynamics of protease variants during the evolution of
ritonavir resistance. We employed an MSS-HTA capable of
detecting mutations at HIV-1 protease codon positions 46, 48,
54, 82, 84, and 90 (55) to investigate the population dynamics
of pro variants underlying the evolution of RTV resistance in a
set of subjects failing RTV therapy. The MSS-HTA separates
heteroduplexes formed between RT-PCR products of pro vari-
ants and a radioactively labeled DNA probe in a native poly-
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acrylamide gel largely by changes at these target positions and
allows reliable quantitation of the frequency of protease alleles
exceeding an abundance of 3% (55). All amplifications and
MSS-HTAs were carried out in duplicate, and any samples
with discordant HTA banding patterns were excluded from
this study. This assured that the amplifications contained
enough template strands to form a representative sample of
the total population.
Figures 1 through 3 summarize the patterns of evolution
observed in 17 subjects on RTV, as well as the changes in
HIV-1 RNA load and CD4 T-cell levels over the course of
the treatment period. Figure 1 shows subjects with a 300-fold
or greater initial reduction of virus load in response to RTV
therapy, Fig. 2 shows subjects with a 100- to 300-fold initial
reduction of virus load, and Fig. 3 shows subjects with a 2- to
100-fold initial reduction of virus load. All subjects, irrespec-
tive of the magnitude of virus load reduction, displayed one to
several steps of adaptive evolution following the introduction
of RTV. In most subjects, the initial change in the virus pop-
ulation was concurrent with virus load rebound or nadir and
occurred a mean of 90 days (range, 29 to 193 days) after
treatment initiation. The timing and rates of population turn-
overs as well as the number of detectable variants present
concurrently (range, 1 to 7; for example, compare subjects
1157 and 1148 in Fig. 1) varied considerably between subjects.
No sequence changes were detected by the MSS-HTA (Fig. 4)
and sequence analysis (data not shown) in matched subjects on
the placebo arm of the same study over the same period of
time.
Maintenance of populations without primary resistance mu-
tations. In 6 of the 17 studied subjects (1051, 1157, 1115, 1093,
1068, and 1113) detectable amounts of pro variants with MSS-
HTA mobility identical to pretreatment variants were main-
tained late in the trial period in the face of the emergence of
variants with considerable mobility shifts. Sequence analysis of
clones representing each HTA band showed that the high-
mobility bands represented variants that were closely related
or identical to pretreatment variants and had not acquired any
known RTV resistance mutations over the course of treatment.
However, the low-mobility bands represented variants that had
acquired RTV resistance mutations. This indicated that vari-
ants with low resistance could be maintained at a level of 4 to
20% in the face of the evolution of more resistant variants
under selective pressure from RTV.
Sequence evolution of pro variants. The sequence corre-
sponding to pro codons 30 to 95 of variants corresponding to a
number of MSS-HTA bands was determined. For homogenous
populations, the RT-PCR product was sequenced directly. If
more than one pro variant was present, RT-PCR products were
cloned and several clones corresponding to each MSS-HTA
band were subjected to sequencing. As has been described
previously for subjects failing RTV therapy (18, 43), this first
step of evolution included a mutation at position 82 in all 17
virus variants that emerged between days 29 and 120 after
treatment start (Fig. 5). The I54V mutation was present in
approximately 20% of early rebound variants as well. Subse-
quent turnovers were associated with the emergence of strains
with additional mutations at positions 46, 54, 84, and 90 (Fig.
5).
Each new MSS-HTA band represented a variant with a
mean of 1.8 new coding mutations compared to variants
present at the preceding time point. A mean of 1.3 of these
mutations was found at positions associated with reduced RTV
susceptibility (positions 36, 46, 54, 71, 77, 82, 84, 90). The
cumulative number of RTV resistance-associated mutations
increased significantly with time (  0.58; P 	 0.0001), but the
number of mutations outside these positions did not. The rate
of accumulation was significantly higher during the first 120
days of treatment (0.035 mutation per day) than during the
remainder of the trial period (0.016 mutation per day; P 
0.047).
Evolution of viral fitness in vivo. The relative fitness of
newly emerging pro variants was determined using a model
proposed by Holland et al. (27a). In this model, the slope of
the line obtained by plotting the logarithm of the ratio of two
variants or one variant and all other variants against time in
generations is interpreted as the selective advantage of the
variant (20). The relative fitness, or fold change of the ratio per
generation, is equal to eslope. A representative example for this
analysis is shown in Fig. 6A. When the analysis was carried out
for all emerging variants that coexisted with the preceding
variants for more than two consecutive time points, the mean
relative fitness of new variants compared to the preceding
variants was 1.2 (range, 1.02 to 1.76; Fig. 6B). Note that this
analysis excluded the first step of resistance evolution due to its
speed, which did not allow for coexisting variants. Note also
that the estimate used for the HIV-1 generation time was 2.3
days (26, 38, 48, 49, 53, 68).
Evolution of drug susceptibility. To examine the evolution
of phenotypes, a fragment spanning protease from the 3 end
of p6 to the 5 end of reverse transcriptase was amplified from
three time points from each of three subjects and a single
representative sequence for each HTA band present in the
samples was selected and subjected to drug susceptibility test-
ing as described previously (50). In Table 1 the fold suscepti-
bility reduction is shown for all tested drugs. In all cases but
one, the drug susceptibility of the entry sample was within
twofold of the NL4-3 control for all tested inhibitors.
RTV resistance increased in successive time points and was
associated with significant cross-resistance to lopinavir (P 	
0.0001), nelfinavir (P  0.003), and indinavir (P  0.0001).
Hypersusceptibility (50% inhibitory concentration of 	0.4) to
two protease inhibitors (saquinavir and amprenavir) was ob-
served with sequences derived from two subjects. Note, how-
ever, that only one sequence displayed amprenavir hypersus-
ceptibility and that this sequence also displayed low overall
luciferase activity in the target cells, making the measured drug
susceptibility less reliable. Hypersusceptibility to either of the
two nonnucleoside reverse transcriptase inhibitors nevirapine
(P  0.01) and efavirenz (P  0.02) was associated with RTV
resistance. Note that only the first 18 amino acids of reverse
transcriptase in the resistance assays were encoded by patient-
derived sequences, suggesting that the observed RT inhibitor
hypersusceptibility is attributable to the changes in protease.
Evolution of replication capacity and specific infectivity in
the absence of RTV. The protease sequences tested for drug
susceptibility were introduced into infectious molecular clones
and used to test specific infectivity (infectious units [IU]/ng CA
or IU/RT activity) and RT/CA ratio in supernatant virus par-
ticles. In addition, the vector system used for drug susceptibil-
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FIG. 1. Dynamics of protease variants during ritonavir resistance evolution in subjects with a transient virus load reduction of greater than
300-fold. Dynamics were analyzed with a multiple site-specific HTA which displays mobility shifts in response to mutations at positions 46, 48, 54,
82, 84, and 90 in protease. Each band represents a protease variant and is assigned a number on the left. The position of the labeled probe strand
annealed to a fully complementary strand is indicated (double-stranded probe; dsP). In addition, the viral load (filled circle) and the concentration
of CD4 T cells (open squares) are shown for each subject in the right column. Arrows in the viral load graphs indicate protease alleles that were
introduced into molecular clones.
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ity testing was also employed to determine replication capacity
during a single replication cycle (luciferase activity in infected
cells/luciferase activity in transfected cells). We have shown
previously that these single-cycle assays can reflect relative
fitness accurately (56). The results of these analyses are sum-
marized in Fig. 7.
There were two patterns of evolution of specific infectivity.
In one subject (1035), specific infectivity decreased with the
initial rebound of virus load and with subsequent selection of
higher resistance in the face of continued ritonavir selection. In
the other two subjects, specific infectivity was reduced at the
time of virus load rebound but remained stable during subse-
quent decreases in ritonavir susceptibility. Wild-type-like spe-
cific infectivity was not restored in any subject by mutations in
the pro-spanning fragment used in this experiment. No signif-
icant differences between the RT/CA ratios were found be-
tween the infectious clones with patient-derived protease se-
quences. Single-cycle replication capacity, as measured with
the resistance-testing vectors, showed similar patterns, but in
several cases the absolute values were lower for pro sequences
carrying resistance mutations when compared to the specific
infectivity assay, as has been noted previously (56).
We observed a negative correlation between reduced RTV
susceptibility and specific infectivity for 9 of the 11 clones in
FIG. 2. Dynamics of protease variants during ritonavir resistance evolution in subjects with a transient 100- to 300-fold virus load reduction.
Otherwise as described in the legend to Fig. 1.
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this study (  0.83; P  0.008). The two clones that dis-
played the greatest reduction of ritonavir resistance did not fit
this pattern. This may suggest that the protease sequences in
these clones had undergone some compensation that attenu-
ated the negative fitness effect of further resistance mutations.
Note that all fitness measurements were carried out in the
absence of protease inhibitors and that by definition resistant
variants have a selective advantage in the presence of drug.
FIG. 3. Dynamics of protease variants during ritonavir resistance evolution in subjects with a transient virus load reduction of more than 2- to
100-fold. Otherwise as described in the legend to Fig. 2.
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Evolution of sequence changes in Gag. The evolution of
high-level resistance to protease inhibitors can be accompa-
nied by compensatory mutations in the processing sites flank-
ing the Gag p1 domain (17, 72). We determined near-full-
length sequence for the gag gene at entry and day of
termination for five subjects who displayed multistep evolution
of the viral pro gene (1137, 1035, 1098, 1144, 1147). In three
cases the p2 (the position 2 amino acid upstream of the cleav-
age site) Ala of the NC-p1 processing site was mutated to Val
in comparing the entry to the termination sequences; in one
case the p1 (the position just downstream of the cleavage site)
Leu of the p1/p6 site was mutated to Phe (1144), and in the
remaining case there were no processing site mutations (1147).
These observations are consistent with the evolution of high-
level resistance while the subjects were maintained on RTV
therapy after virus rebound.
It has also been reported that nonprocessing site mutations
are selected in the gag gene during selection for protease in-
hibitor resistance in cell culture using four different inhibitors
(21). We have confirmed this observation in part by examining
viruses that were selected in cell culture for high levels of
resistance to protease inhibitors (67). However, in examining
the gag genes of the five subjects cited above, we found no
evidence for a similar pattern of mutations after selection of
protease inhibitor resistance in vivo.
The extent of processing at the NC-p1 junction correlates
with specific infectivity. The processing of the polyproteins
Gag and Gag-Pro-Pol by protease is an obligatory step in the
formation of infectious particles. We analyzed the processing
of the NC-p1 and CA-p2 sites which have been implicated in
contributing to the loss of fitness associated with protease
inhibitor resistance. Incomplete processing of the CA-p2 and
NC-p1 cleavage sites was apparent (Fig. 8A). The impact of the
resistance mutations on CA-p2 processing was subtler than the
impact on NC-p1 processing. We hypothesized that the aber-
rant processing of cleavage sites flanking NC was closely linked
to the observed loss of fitness, consistent with these sites being
the most frequently mutated cleavage sites in Gag-Pro-Pol (12,
36, 72). In agreement with this hypothesis, there was a signif-
icant correlation (  0.94; P 	 0.0001) between the specific
infectivity and the fraction of NC-p1 sites processed (Fig. 8B).
DISCUSSION
We investigated the population genetics of ritonavir resis-
tance evolution in subjects who participated in a ritonavir ef-
ficacy trial (7) using an MSS-HTA (55). The MSS-HTA re-
vealed multiple steps of sequence evolution among all of the
examined subjects on the RTV treatment arm (Fig. 1 to 3) and
did not detect any sequence changes among five subjects on the
placebo arm (Fig. 4). Thus the MSS-HTA proved to be a
sensitive tool for resolving pro sequence populations during the
evolution of RTV resistance. One advantage of this pro MSS-
HTA was that distinct sequence variants were separated based
FIG. 4. Dynamics of protease variants in the absence of ritonavir
analyzed by a multiple site-specific HTA. For five subjects, the pro-
tease populations at the beginning of the trial (day 1) and the end of
the blinded phase (around day 250) were compared. No significant
changes were detected over the observation period. hd, heteroduplex;
dsP, double-stranded probe.
FIG. 5. Changes in the coding sequence of protease over the course of treatment. The sequences of 53 protease variants were determined as
the consensus sequence of multiple clones per variant. Indicated in this stacked bar graph are the percentage of variants that showed differences
with the clade B consensus sequence at the indicated resistance-associated positions. The first bar (A) in each group reflects amino acid changes
present at trial entry, the second bar (B) reflects the amino acid composition of variants that arose between entry and day 120, and the third bar
(C) reflects the composition of variants that arose after day 120. Letters indicate mutant amino acids. Note the increase of mutations at positions
82, 46, 54, 84, and 90.
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on linked sequence differences, allowing the quantitation of
discrete genotypic variants. However, consistent with previous
observations (data not shown), the initial mutation in a pro
variant generally resulted in a larger heteroduplex mobility
shift than subsequent mutations occurring in the background
of an already mutated protease.
Sequence analysis showed that each new protease variant
that emerged carried a mean of 1.8 (range 1 to 4) new coding
mutations compared to previously existing variants, 1.4 (range
1 to 3) of which were at positions previously implicated in
ritonavir resistance. We were not able to determine if more
than one mutation emerged in a single step or if mutations
accumulated one at a time. The mutations observed here
match those previously described both in sequence identity and
in the order of accumulation (18, 43). The accumulation rate of
resistance-associated mutations was highest following the on-
set of RTV therapy and with time asymptotically approached
an estimated 0.016 mutation/day. Each of the evolutionary
steps was associated with a mean 1.2-fold increase in relative
fitness in the presence of RTV. This is an underestimate of the
actual gains because the analysis excluded for technical reasons
turnovers that occurred rapidly without displaying any coexist-
ence of the emerging variant with the preceding variant. This
FIG. 6. (A) Determination of relative fitness of pro variant 5 in
subject 1008. The logarithm of the ratio of variant 5 (virus 1) and the
other variants present at the same time (virus 2) was plotted against
time in generations. The rate of change was determined by linear
regression, and eslope was computed as an estimate for the relative
fitness of variant 5 compared to the other variants present. (B) Fold
fitness increases associated with the steps of adaptive evolution. Rel-
ative fitness of all newly emerging pro variants was determined in vivo
as described above and plotted as a scatter graph. The mean of all
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analysis assumes an excess of target cells in vivo; however, the
validity of this assumption is not known.
We demonstrated the maintenance of detectable levels of
drug-susceptible HIV-1 variants concurrently with the evolu-
tion of resistant strains in 6 of 17 subjects. The high degree of
RTV susceptibility of these variants was inferred from the
unchanged MSS-HTA mobility as well as by the absence of
known resistance mutations from protease codons 30 to 95.
Mutations outside this region are generally considered com-
pensatory for the mutations in this fragment of protease.
Moreover, in some cases complete protease sequences were
available and did not show any resistance-associated mutations
in the strains with high MSS-HTA mobility. Thus we believe
that we are observing the persistence of nonresistant variants
in a mixture with resistant variants in up to one-third of the
subjects. There are several possible explanations for the per-
sistence of wild-type-like pro alleles concurrently with alleles
with reduced drug susceptibility. We do not believe that these
sequences represent archived viral genomes present in con-
taminating DNA given their steady levels in the longitudinal
samples from specific subjects and complete absence in others.
Therefore, there must be one or more mechanisms for the
maintenance of actively replicating parental sequences in the
face of drug selective pressure. First, poor compliance or phar-
macokinetic issues may lead to intermittently suboptimal RTV
concentrations allowing residual replication of more highly
susceptible variants. In two cases (subjects 1115 and 1113) the
reappearance of a variant with wild-type mobility and the viral
load changes suggest that poor compliance might indeed ac-
count for the persistence of the wild-type pro sequences. Sec-
ond, variants with high RTV susceptibility could be replicating
in RTV-inaccessible compartments, such as the central ner-
vous system (23, 33, 66). And third, the fitness loss associated
with the evolution of resistance in the sequence background of
these pro genes may have resulted in fitness levels that were
similar to those of the wild type in the presence of RTV. The
patterns of evolution in the four remaining subjects in which
pro variants with resistance-associated mutations evolved with
rates comparable to those of the rest of the 17 subjects despite
the maintenance of wild-type variants are consistent with the
latter two possibilities.
Susceptibility to ritonavir decreased during the treatment
period, as expected. Other protease inhibitors with overlapping
resistance mutation profiles had reduced activity against the
ritonavir-resistant strains as well. However, susceptibility to
two protease inhibitors, saquinavir and amprenavir, increased
in three of the analyzed variants that had significant reduction
of RTV susceptibility. A more consistent negative correlation
between RTV resistance and susceptibility to the reverse tran-
scriptase inhibitors nevirapine and efavirenz was observed as
well. One possible explanation is that the hypersusceptibilities
were due to a reduction of virion-associated protease activity
and hence reduced fitness. In this model, the reduced protease
activity in the virus particles would lead to incomplete process-
ing of the Gag-Pro-Pol polyprotein leading to hypersuscepti-
FIG. 7. Specific infectivity and replication capacity of clones bear-
ing protease sequences derived from study subjects. A protease se-
quence representative of each variant present at the beginning (day 1
[d1]), a time point close to virus load rebound (month 4 [m4], m5, or
m6), and the last available time point (m12) in subjects 1035, 1118, and
1137 was introduced into a molecular infectious clone. To determine
specific infectivity, molecular clones were transfected into 293 cells in
triplicate, virus supernatants were collected, and the titer, the reverse
transcriptase activity, and the concentration of the capsid protein were
determined. Specific infectivity is given relative to the parental strain
as the ratio of titer to RT activity (open bars) or the ratio of titer to
capsid protein (light gray bars). Replication capacity (RC [dark gray
bars]) was determined in a single-cycle replication assay with a lucif-
erase-encoding pseudotyped vector system as described previously (8,
50).
FIG. 8. Correlation of the fraction of processed NC-p1 sites and
specific infectivity. (A) Virions were concentrated by purification, and
pelleted virus proteins were separated by SDS-PAGE, blotted to poly-
vinylidene difluoride membranes, and detected immunologically with
human serum from an HIV-1-infected person (top blot) or a poly-
clonal anti-NC-p1-p6 antibody. Mutant proteases are described by
subject of origin and time point of sampling. wt, parental infectious
clone; D25A, parental infectious clone with the protease-inactivating
D25A mutation as a negative control for processing. (B) The fraction
of processed NC-p1 sites was normalized to the parental strain and
correlated with the specific infectivity (see Fig. 7) for each variant. Also
shown is the best-fit linear regression line.
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bility to a tightly binding reverse transcriptase inhibitor, in a
way that is analogous to the observation that resistance to a
protease inhibitor increases susceptibility to zidovudine (16,
35). The same model could also be used to explain the hyper-
susceptibility to two of the protease inhibitors where the se-
lected mutations did not provide cross-resistance. However, we
cannot exclude the possibility that some RTV resistance-asso-
ciated mutations simply enhance binding of some inhibitors, as
has been suggested for some reverse transcriptase inhibitors
(69).
Specific infectivity (a surrogate marker for fitness) of recom-
binant virus strains bearing pro sequences derived from three
subjects after treatment was reduced to between 4 to 65% of
the pretreatment infectivity (Fig. 7). Even after up to 12
months of RTV treatment and in the presence of several pro
mutations that could be considered compensatory in nature,
none of the resistant variants recovered pretreatment-specific
infectivity levels, consistent with observations made by others
(2). The reversion of resistant virus populations to drug-sus-
ceptible populations even after prolonged treatment failure
(12 months) also suggests that compensation is indeed in-
complete (15, 18, 24, 30). The infectivity measurements pre-
sented here are consistent with the infectivity of single-, dou-
ble-, and triple-mutant strains described by Mammano et al.
(37) but lower than the fitness of clones harboring multiple
resistance mutations measured by coculture experiments (40,
44). This difference may be partially accounted for by compen-
satory alanine-to-valine mutations at the P2 position of the
NC-p1 cleavage site seen in two of the three subjects tested
here at trial termination (subjects 1035 and 1137) but not
included in the sequences used to test replication capacity. In
contrast to previously reported findings (16), we did not detect
significant differences in the amount of particle-associated RT
activity in the infectious clones presented here.
We found the processing of Gag to be incomplete in infec-
tious clones harboring protease sequences derived from the
RTV-treated subjects. This has been noted previously (13, 14,
59, 71). However, here we showed that the reduction in pro-
cessing of the NC-p1 cleavage site correlated significantly with
the reduction in specific infectivity (Fig. 8). This is consistent
with the finding that mutations in the protease cleavage sites at
NC-p1 and p1-p6 are selected in vivo by a protease inhibitor-
containing regimen (12, 17, 37, 72) and that these mutations
can partially compensate for the loss of fitness associated with
protease resistance mutations (37, 72).
It will be important to examine a larger set of clinical isolates
with resistance to protease inhibitors to confirm the correlation
between incomplete NC-p1 processing and decreases in fitness
of these viruses. Loss of fitness through this mechanism may
contribute to the disconnect phenotype in which CD4 cell
gains are maintained in the face of an actively replicating
drug-resistant virus variant (2, 15, 65). The mechanism by
which underprocessed NC-p1 reduces infectivity remains to be
explored.
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